Hydrazinecarbothioamide, 2-[1-(2-thienyl)ethylidene]-, (2Z)-

SSAA09E1 is a cathepsin L blocker (IC50: 5.33 μM).SSAA09E1 inhibits stages of viral entry. SSAA09E1 can be used for SARS-CoV infection research[1]

SSAA09E1 is an inhibitor of severe acute respiratory syndrome coronavirus (SARS-CoV) viral entry.1 It reduces infection of HEK293T cells transiently transfected with angiotensin-converting enzyme 2 (ACE2) by an HIV-based virus system pseudotyped with SARS-CoV surface glycoprotein (EC50 = 6.7 μM). SSAA09E1 also inhibits the proteolytic activity of cathepsin L (IC50 = 5.33 μM) but not cathepsin B when used at a concentration of 20 μM.

1.()